Citius Oncology (CTOR) Non-Current Deferred Tax Liability (2023 - 2026)

Citius Oncology's Non-Current Deferred Tax Liability history runs 4 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Non-Current Deferred Tax Liability rose 24.88% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (up 24.88% YoY), while the FY2025 annual figure was $2.8 million, up 61.17% from the prior year.
• Non-Current Deferred Tax Liability was $2.8 million for Q1 2026 at Citius Oncology, down from $3.0 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $3.0 million in Q4 2025 to a low of $1.2 million in Q3 2023.
• Historically, Non-Current Deferred Tax Liability has averaged $2.3 million across 4 years, with a median of $2.4 million in 2025.
• The sharpest annual moves came in 2025 and 2026: Non-Current Deferred Tax Liability surged 61.17% in 2025, then rose 24.88% in 2026.
• A 4-year view of Non-Current Deferred Tax Liability shows it stood at $1.2 million in 2023, then soared by 72.94% to $2.0 million in 2024, then soared by 53.05% to $3.0 million in 2025, then decreased by 7.58% to $2.8 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $2.8 million (Q1 2026), $3.0 million (Q4 2025), and $2.8 million (Q3 2025), per Business Quant data.